Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

The team found that the tirzepatide-treated mice lost about 20 percent of their body weight, mostly from reduced fat mass. In ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

New research reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Experts urge ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Clinical trial data review on weight-loss drugs reveals weight regain patterns post-medication discontinuation, impacting weight management strategies.

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...